

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/501,453
Filing Date	January 14, 2003
First Named Inventor	William Herman
Art Unit	1644
Examiner Name	Phuong N. Huynh
Attorney Docket Number	HER1-006

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Blok et al., "A Bispecific Monoclonal Antibody Directed Against Both the Membrane-Bound Complement Antibody Directed Against Both the Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 enhances C3 Deposition and Tumor Cell Lysis by Complement", <i>The Journal of Immunology</i> , 1999, No. 160, pp. 3437-3443, The American Association of Immunologists	
		Harris et al., "Tumor Cell Killing Using Chemically Engineered Antibody Constructs Specific for Tumour Cells and the Complement Inhibitor CD59", <i>Clinical and Experimental Immunology</i> , 1997, No. 107, pp. 364-371, Blackwell Science	
		Gelderman et al., "Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Cry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model", <i>Cancer Research</i> , June 15, 2004, No. 64, pp. 4366-4372	
		Gelderman et al., "The Inhibitory Effect of CD48, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies", <i>Laboratory Investigation</i> , 2002, No. 82, pp. 483-493	
		Gelderman et al., "Enhancement of the Complement Activating Capacity of 17-1A mAb to Overcome the Effect of Membrane-Bound Complement Regulatory Proteins on Colorectal Carcinoma", <i>Eur. J. Immunol.</i> , 2002, no. 32, pp. 128-135, WILEY-VCH Verlag GmbH, Weinheim, Germany	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.